TRAILBLAZER-ALZ, a clinical drug study for people in early stages of Alzheimer’s disease.
Conducted at the Bruyère Research Institute, OttawaContact:
The Bruyère Research Institute is looking for participants to be part of a clinical drug study in dementia.
The TRAILBLAZER-ALZ study conducted at Bruyère Research Institute will look at whether an investigational drug, Donanemab, can help slow or stop memory loss in people with early stages of Alzheimer’s disease.
Recent results indicated that the drug significantly slowed cognitive and functional decline in patients with Alzheimer's disease by 32 percent compared with placebo. The study will also test whether an experimental blood test can detect the presence of Alzheimer’s disease.
From more information, visit https://trailblazer2study.com/
This international pivotal clinical drug study has been approved by The Bruyère Research Institute Ethics Board
Last updated: 2021-05-18